You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Bexsero

Product menu

Resources

Materials and information to support your practice and your patients.

Mechanism of action

BEXSERO-an innovative vaccine developed to achieve a robust immune response1

Learn about reverse vaccinology 

BEXSERO works across age groups against a range of diverse MenB strains1

  • MenB strains are highly variable in the types and amounts of antigens they express2
  • By targeting four distinct antigens, BEXSERO offers the potential to protect against invasive MenB strains, even when the expression of one component is low or antigenically different1,3,4
  • This multiple-antigen approach in BEXSERO may provide synergistic killing and improve strain coverage4,5

BEXSERO uniquely targets four distinct antigens-fHbp, NadA, PorA P1.4, and NHBA2

  • Factor H binding protein (fHbp) binds factor H, which enables bacterial survival in the blood6
  • Porin A (PorA) P1.4, part of outer membrane vesicles, has been shown to induce strain-specific bactericidal response7
  • Neisseria heparin-binding antigen (NHBA) binds heparin, which may promote bacterial survival in the blood8
  • Neisserial adhesion A (NadA) mediates binding to and entry into human epithelial cells9

BEXSERO was developed by Chiron Vaccines in association with the Norwegian Institute of Public Health.7

Resources for parents

woman woman

Here are 3 measures to approaching parents about prevention of MenB

EDUCATE

parents about the seriousness of MenB 

  • Share facts from the IMD section of this website 

COMMUNICATE

the importance of vaccination with BEXSERO for eligible patients

  • Initiate the discussion 
  • Electronic health records can identify eligible patients

VACCINATE

your vulnerable patients

  • Electronic health records reminders can help keep them on schedule
  • Text messages and emails can help ensure they complete the series

HCP-Parent Discussion Guide

For engaging parents about MenB vaccinations for their children

Download

Bexsero Safety Information2

Contraindications2 : 
Hypersensitivity to the active substances or to any of the excipients listed as below

Warning and precautions2: 
As with other vaccines, administration of Bexsero should be postponed in subjects suffering from an acute severe febrile illness. However, the presence of a minor infection, such as cold, should not result in the deferral of vaccination

Adverse Events2 : 
Very Common : sleepiness, unusual crying, headache Uncommon: seizures (including febrile seizures)
Not known: hypotonic-hyporesponsive episode, meningeal irritation (signs of meningeal irritation, such as neck stiffness or photophobia, have been sporadically reported shortly after vaccination. diarrhoea, vomiting

References:

  1. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490–19495. 
  2. Bexsero Prescribing Information.
  3. Medini D, Stella M, Wassil J. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629–2636. 
  4. Rappuoli R, Pizza M, Masignani V, Vadivelu K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17(12):1111–1121.
  5. Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study [published correction appears in Lancet. 2015 May 2;385(9979):1728]. Lancet. 2012;379(9816):617–624. 
  6. Schneider MC, Prosser BE, Caesar JJE, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009;458(7240):890–893. 
  7. Martin DR, Ruijne N, McCallum L, O’Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 2006;13(4):486–491. 
  8. Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA. 2010;107(8):3770–3775. 
  9. Capecchi B, Adu-Bobie J, Di Marcello F, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol. 2005;55(3):687–698.

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK group of companies or its licensor. All rights reserved. 

PM-RCH-BEX-WCNT-240001 Date of preparation: July 2024